SCHEDULE: Squadron Entities Report 6.6% Stake in Spruce Biosciences

Squadron Master Fund LP and related entities have disclosed beneficial ownership of up to 6.6% of Spruce Biosciences, Inc. common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have filed a Schedule 13G disclosing their beneficial ownership in Spruce Biosciences, Inc.
• Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank each beneficially own 70,000 shares of common stock, representing 6.6% of the class.
• Squadron Master Fund LP beneficially owns 62,000 shares of common stock, representing 5.8% of the class.
• The ownership percentages are calculated based on 1,065,223 shares of common stock outstanding, which includes 502,181 shares issued in a private placement announced on October 8, 2025.
• The reporting persons disclaim beneficial ownership over the securities, stating they were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment in Spruce Biosciences, which can be viewed as a vote of confidence. While the filing itself is a factual ownership disclosure, the entry of a new substantial investor is generally a positive signal.

Positives

• A significant institutional investor, Squadron Master Fund LP and its affiliates, has taken a substantial stake (over 5%) in Spruce Biosciences, which can be viewed as a vote of confidence in the company's prospects.

Industry Context

This filing indicates a new institutional investment in Spruce Biosciences, Inc., a company operating in the biotechnology sector. Such investments can signal growing interest or confidence in the company's specific therapeutic areas or overall market position.

Stakeholder Impact

• Shareholders may perceive the new institutional investment as a positive indicator of the company's value and future prospects, potentially influencing stock price.

Key Dates

Recommendation

The disclosure of a significant institutional stake by Squadron Master Fund LP and its affiliates suggests a vote of confidence in Spruce Biosciences. While this filing does not provide operational or financial performance data, the entry of a new substantial investor typically signals potential upside or stability, warranting a 'hold' recommendation for existing investors and further due diligence for potential new investors.

Keywords

Spruce Biosciences, Squadron Master Fund, Squadron Capital Management, Matthew Sesterhenn, William Blank, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Private Placement